FMP
Larimar Therapeutics, Inc.
LRMR
NASDAQ
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
6.38 USD
-0.67 (-10.5%)
About
ceo
Dr. Carole S. Ben-Maimon M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.larimartx.com
exchange
NASDAQ
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
CIK
0001374690
ISIN
US5171251003
CUSIP
517125100
Address
Three Bala Plaza East
Phone
844 511 9056
Country
US
Employee
42
IPO Date
Jun 19, 2014
Key Executives
